Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$103.54 USD

103.54
2,057,483

+0.17 (0.16%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $103.52 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for NXP Semiconductors' (NXPI) Q1 Earnings?

by Zacks Equity Research

NXP Semiconductors' (NXPI) first-quarter results will likely reflect strength across Industrial & IoT and Mobile end markets. However, weakening demand in the Automotive segment may have been a concern.

Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings

by Zacks Equity Research

GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

What's in Store for Charter Communications (CHTR) in Q1 Earnings?

by Zacks Equity Research

Charter Communications' (CHTR) first-quarter 2024 performance is likely to have benefited from its expanding broadband network despite stiff competition and slow subscriber addition.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

by Zacks Equity Research

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Cardinal Health (CAH) closed the most recent trading day at $103.37, moving +0.53% from the previous trading session.

What's in Store for STMicroelectronics (STM) in Q1 Earnings?

by Zacks Equity Research

STMicroelectronics' (STM) first-quarter results are expected to reflect strength in the automotive market. However, weakening demand across the personal electronics market is a concern.

Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries

by Zacks Equity Research

Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.

Is Trending Stock Cardinal Health, Inc. (CAH) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.

Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing

by Zacks Equity Research

Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.

Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

SNAP Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

SNAP's first-quarter 2024 results are likely to reflect the steady usage of the Snapchat platform, boosted by growing AI efforts and subscribers.

Lam Research (LRCX) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Lam Research's (LRCX) third-quarter fiscal 2024 results are expected to reflect strength in 3D DRAM and advanced packaging amid a slowdown in memory spending.

GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging

by Zacks Equity Research

GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

by Zacks Equity Research

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

What's in Store for Texas Instruments (TXN) in Q1 Earnings?

by Zacks Equity Research

Texas Instruments' (TXN) first-quarter 2024 results are likely to reflect the adverse impacts of inventory reduction and macro headwinds.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

by Zacks Equity Research

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

by Zacks Equity Research

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

by Zacks Equity Research

GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

by Zacks Equity Research

Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

What's in Store for Taiwan Semiconductors' (TSM) Q1 Earnings?

by Zacks Equity Research

Taiwan Semiconductor's (TSM) first-quarter 2024 results are expected to reflect gains from its robust technology portfolio amid headwinds.